The Supreme Court on Thursday blocked a federal appeals court ruling that would have restricted mail-order access to the abortion drug mifepristone, keeping current distribution rules in place while litigation continues. Justices Samuel Alito and Clarence Thomas each filed separate dissents, and neither pulled punches.

The order halted a May 1 decision by the New Orleans-based U.S. Court of Appeals for the 5th Circuit that had reinstated an in-person visit requirement to obtain the drug. Drugmakers Danco and GenBioPro, which manufacture the brand-name and generic versions of mifepristone, had brought an emergency application asking the high court to intervene, as The Hill reported.

The case now returns to the 5th Circuit. But the dissents from Thomas and Alito signal that at least two members of the Court believe the majority got this one badly wrong, and that the legal fight over mifepristone is far from settled.

Thomas invokes the Comstock Act

Justice Thomas grounded his dissent in an argument he has raised before: that an 1873 federal anti-obscenity statute, the Comstock Act, already makes mailing mifepristone a criminal offense. He framed the drugmakers' request in blunt terms.

"Applicants are not entitled to a stay of an adverse court order based on lost profits from their criminal enterprise. They cannot, in any legally relevant sense, be irreparably harmed by a court order that makes it more difficult for them to commit crimes."

Thomas had repeatedly referenced Comstock during oral arguments in a 2024 case about mifepristone. That earlier case ended with the Court unanimously upholding access to the drug, but only on a technicality, ruling that doctors and medical groups opposed to abortion did not have standing to sue.

The standing question dodged the substance. Thomas's dissent this week suggests he has no intention of letting the underlying legal question stay unanswered. Justice Alito, who by default handles emergency matters arising from the 5th Circuit, had recently returned to public duties and briefly put the 5th Circuit ruling on hold before the full Court weighed in.

Alito: an 'unreasoned order'

Alito's dissent struck a different chord. He called the majority's decision to grant the stay "remarkable", and not as a compliment.

"The Court's unreasoned order granting stays in this case is remarkable. What is at stake is the perpetration of a scheme to undermine our decision" overturning constitutional abortion rights.

That language carries weight. Alito authored the Dobbs opinion that overturned Roe v. Wade nearly four years ago. His dissent here reads as a warning that the regulatory apparatus around mifepristone is being used to circumvent what the Court decided in Dobbs, allowing abortion access through the mail even in states that have enacted near-total bans.

Alito has been an active and outspoken presence on the bench in recent months. He sharply rebuked Justice Ketanji Brown Jackson in a separate Louisiana-related order, reflecting a Court where internal tensions run high and the conservative wing is not shy about making its disagreements public.

Louisiana's challenge and the FDA's 2023 rule

The underlying lawsuit was brought by Louisiana, which sued the Food and Drug Administration over a 2023 regulation that allowed mifepristone to be prescribed through telehealth, dispensed at pharmacies, and shipped through the mail. Louisiana argued the rule undercut its near-total abortion ban and violated state sovereignty. The state also contended the FDA lacked sufficient safety data to justify the expanded access.

Louisiana Attorney General Liz Murrill, a Republican, did not mince words after the Court's order came down.

"It's shocking that the Supreme Court would block this common-sense return to medically ethical practices and oversight."

She followed up with a pointed jab at the Justice Department's role, or lack thereof, in the case.

"DOJ did not defend Big Pharma, which is profiting from the illegal and unethical distribution of abortion pills. We will keep fighting."

The Justice Department had told the appeals court that Louisiana's lawsuit "would disrupt FDA's ongoing review, and usurp FDA's scientific role, but would also threaten chaos." The FDA is currently reviewing the safety protocols for mifepristone, though no timeline for completing that review has been disclosed.

The broader dynamics within the Court itself have drawn attention this term. Solo dissents and sharp rebukes from justices across the ideological spectrum have become a recurring feature, suggesting a bench where consensus is increasingly hard to find.

The drugmakers respond

GenBioPro CEO Evan Masingill issued a statement framing the outcome as a preservation of the status quo.

"With today's Supreme Court decision, Americans' access to mifepristone remains unchanged for now. GenBioPro is continuing to serve its customers and is committed to providing our evidence-based, essential medication to all who need it."

Danco, the manufacturer of the brand-name version, pointed to the drug's long regulatory track record.

"Over the years, FDA has reviewed extensive safety and effectiveness data from dozens of clinical trials and decades' worth of real-world experience in millions of patients."

The company added that it was "confident that a review of all recent, reliable data by FDA will continue to show that Mifeprex is very safe and effective." Mifepristone is typically used as part of a two-drug combination for medication abortion.

The Court's decision to grant the stay does not resolve the merits. It simply keeps the 2023 FDA rules in place while the 5th Circuit continues to hear the case. The Supreme Court could ultimately receive the dispute again on its normal docket, a prospect that both sides are clearly preparing for.

What comes next

The procedural posture matters. The 5th Circuit will now take up the case again with the stay in place, meaning mifepristone distribution continues under the 2023 rules for the foreseeable future. But the dissents from Thomas and Alito lay down markers that will shape the next round of arguments.

Thomas's Comstock Act theory, if it ever commands a majority, would not merely restrict how the drug is distributed. It would make mailing it a federal crime, full stop. That is a far more sweeping outcome than anything Louisiana's lawsuit seeks. And Alito's framing, that the current regulatory regime amounts to a "scheme to undermine" Dobbs, gives future challengers a roadmap for arguing that the FDA's 2023 rule is constitutionally suspect.

For pro-life advocates, the dissents offer both frustration and hope. The majority declined to let the 5th Circuit's order stand, which means mail-order abortion pills continue flowing into states that have banned the procedure. But two justices made clear they view that arrangement as legally indefensible.

The internal maneuvering at the Court has been unusually visible this term, with justices on both sides willing to air disagreements in public filings rather than behind closed doors. This case fits the pattern.

Meanwhile, the FDA's ongoing safety review hangs over the entire dispute. If the agency tightens its own protocols, some of Louisiana's arguments could become moot. If it doesn't, the state will have fresh ammunition when the case returns to the appellate level, and potentially to the Supreme Court itself.

The visibility of the justices in the current political moment only adds to the stakes. Every order, every dissent, every procedural move is scrutinized for signals about where the Court is headed.

The real question

Thursday's order preserves the status quo. It does not settle the law. The majority offered no reasoning, just a stay. Thomas and Alito, by contrast, put their arguments on the record in detail.

Louisiana's near-total abortion ban exists on paper. Whether it can actually function as written depends on whether the federal government can ship the means to circumvent it directly to a patient's mailbox. That tension between state law and federal regulatory power is the core of this fight, and the Court punted on it once before in 2024.

Sooner or later, the justices will have to answer the question they keep avoiding. When they do, the dissents filed Thursday will read less like losing arguments and more like opening briefs.